OJU1 Stock Chart & Stats
€3.60
€0.14(4.04%)
At close: 4:00 PM EDT
€3.60
€0.14(4.04%)
Day’s Range― - ―
52-Week Range€1.74 - €4.32
Previous CloseN/A
Volume0.00
Average Volume (3M)668.00
Market Cap
€146.16M
Enterprise Value€142.67M
Total Cash (Recent Filing)€65.84M
Total Debt (Recent Filing)€761.00K
Price to Earnings (P/E)1.5
Beta0.54
Next Earnings
Jul 14, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.65
Shares Outstanding40,926,083
10 Day Avg. Volume686
30 Day Avg. Volume668
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)59.00
P/FCF Ratio-10.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Very Low LeverageExtremely low debt and sizable equity provide durable financial flexibility, lowering refinancing and insolvency risk. That footing supports continued R&D spending, deal-making or opportunistic asset monetization over months, making the firm less vulnerable to short-term funding shocks.
Proprietary Oral Drug Delivery PlatformA focused oral biologics platform is a structural competitive advantage: high technical barriers and potential for partner licensing or royalties. Platform orientation creates multiple commercialization pathways and durable upside if clinical progress continues, attractive to pharma collaborators.
Asset Monetization And Financing Optionality (Oratech/Lifeward)Monetizing Oratech and securing Lifeward financing creates persistent non-operating cash inflows and equity-linked upside, materially expanding funding options. This structural change reduces sole dependence on equity raises and gives time to advance clinical programs and pursue partnerships.
Bears Say
Zero Or Volatile Product RevenueTTM revenue at zero means the company lacks recurring product sales and depends on sporadic licensing, milestone or financing timing. That structural revenue uncertainty makes multi-month planning and sustainable R&D investment contingent on external deals or asset sales.
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow indicates the business is not self-funding. Over a multi-month horizon this necessitates ongoing financing, partner payments, or asset monetization to sustain operations, constraining strategic flexibility and increasing dilution risk.
Earnings Quality Concerns; Profits Not Backed By CashReported net income gains appear driven by non-operating items rather than core operations. This undermines confidence in durable profitability and could mask underlying operating losses, complicating capital allocation and partner negotiations over the medium term.
Oramed Pharm News
OJU1 FAQ
What was Oramed Pharmaceuticals’s price range in the past 12 months?
Oramed Pharmaceuticals lowest stock price was €1.74 and its highest was €4.32 in the past 12 months.
What is Oramed Pharmaceuticals’s market cap?
Oramed Pharmaceuticals’s market cap is €146.16M.
When is Oramed Pharmaceuticals’s upcoming earnings report date?
Oramed Pharmaceuticals’s upcoming earnings report date is Jul 14, 2027 which is in 347 days.
How were Oramed Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Oramed Pharmaceuticals overvalued?
According to Wall Street analysts Oramed Pharmaceuticals’s price is currently Overvalued.
Does Oramed Pharmaceuticals pay dividends?
Oramed Pharmaceuticals does not currently pay dividends.
What is Oramed Pharmaceuticals’s EPS estimate?
Oramed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oramed Pharmaceuticals have?
Oramed Pharmaceuticals has 40,926,083 shares outstanding.
What happened to Oramed Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oramed Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:OJU1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oramed Pharm Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
82.22%
Trailing 12-Months
Company Description
Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Technical Analysis
―
Whitehawk Therapeutics
―
Quince Therapeutics
―
ALX Oncology Holdings
―
Spruce Biosciences
―